$BKKT

Henderson Joseph Sean-Walsh sold $3K of BKKT

Henderson Joseph Sean-Walsh (Chief Accounting Officer) sold 349 shares of Bakkt, Inc. (BKKT) at $7.93 on 2026-06-25.

Original reporting
SEC EDGAR · Henderson Joseph Sean-Walsh
Published Jun 29, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BKKT
Neutral
high confidence
Mentioned
$BKKT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BKKTNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior (CFO open-market sale) but lacks any fundamental change (no earnings, guidance, or corporate action).

02

Market read

Traders may note the insider sale for sentiment, but the disclosed value is small and unlikely to drive price on its own.

03

What to watch

Transaction size is small ($2.77k) and the filing does not state reasons; traders should avoid over-weighting insider-sale headlines without corroborating company-specific catalysts.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date (2026-06-29) for BKKT insider-sale disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Bakkt, Inc. (BKKT).

Company-level read

Ticker impact

$BKKTNeutralHigh confidence
Context

Bakkt CFO Henderson Joseph Sean-Walsh filed a Form 4 selling 349 shares at $7.93 on 2026-06-25, disclosing new insider activity for BKKT.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with modest size ($2.77k) and no accompanying fundamental catalyst (no guidance, deal, or enforcement action).

Market effects

No clear sector read-through; this is an individual insider sale without broader regulatory or operational context.

None.

None.

Counterpoint

The sale may be non-informational (tax/portfolio rebalancing) and the absence of a 10b5-1 plan is not, by itself, evidence of negative fundamentals.

Key entities

  • Bakkt, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Henderson Joseph Sean-Walsh

    Chief Accounting Officer who sold 349 shares at $7.93 on 2026-06-25.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BKKTMedAI 8/10

Bakkt (BKKT) Q2 2026 Earnings Call Transcript

Bakkt (BKKT) reported Q2 2026 revenue of $170.1 million, down 70% from $568.1 million, citing client transitions and weaker digital asset trading volumes. GAAP net income was $80.8 million, driven mainly by a $98.5 million non-cash gain from Transchem warrants. Total transacting volume was $168.8 million; management reiterated an EBITDA breakeven target in Q4 2026.

$BKKTMed

Bakkt Inc (BKKT) (Q2 2026) Earnings Call Highlights: Strong GAAP Net Income

Bakkt’s CEO Akshay Naheta said the company expects adjusted EBITDA break-even in Q4 2026, without a specific date, citing execution and client activations. Management discussed take rates, cross-border margins, and reaffirmed a 2026 TTV target of about $2.5 billion. The firm outlined post-DTR acquisition progress and Bakkt Agent MAU target of ~25,000 by year-end 2026.

$BKKTMed

Bakkt, Inc. (BKKT): Results of Operations and Financial Condition

Bakkt, Inc. (BKKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bakkt Reports Second Quarter 2026 Results - GAAP net income of $80.8 million, or $1.96 per basic and $1.94 per diluted share - Six commercial offerings live across Bakkt Markets; Total Transacting Volume (“TTV”) of $168.8 million in Q2, including payments volume generated on acqu